The University Hospital Center in Liège is expanding. The new comprehensive cancer center will be ready in 2018. The center focuses on high quality integrated care, and a large part of the building will be dedicated to outpatients in consultation and day-care without overnight hospitalization. The center will offer multidisciplinary care, focused on the overall wellbeing of the patient.
What do Bone Therapeutics, Cardio3 Biosciences and Imcyse all have in common? They focus on stem cell therapy and are all linked to the Laboratory of Cell and Gene Therapy (LTCG) led by Yves Beguin, professor of hematology at the University of Liège and head of the hematology department at the University Hospital Center in Liège. Stem cell research is booming in Wallonia and much of it has originated from the lab of professor Beguin.
Peter Vandenabeele is senior full professor at the Inflammation Research Center (IRC), a VIB department at the Ghent University. He recently published in Nature an original research paper on the regulation of cell survival in vivo (Takahashi et al., 2014). RIPK1 (receptor interacting protein kinase 1) plays an important role both in the survival as well as in the death of epithelial cells. Full knockout mice for the Ripk1 gene are not viable. The team of Vandenabeele managed to make a viable conditional mouse model that lacks Ripk1 only in the intestinal epithelial cells. They also obtained in collaboration with people from GSK (Pennsylvania) a mouse model containing a mutant form of RIPK1 that lacks the kinase activity. Thanks to these genetic mouse models, mechanisms that regulate cell survival and cell death could be explored. Peter Vandenabeele and his team found that the platform function of RIPK lacking the kinase activity is associated with cell survival, while the kinase activity is associated with induction of cell death. Peter Vandenabeele also published a review paper in Nature about cell death pathways and inflammation in early 2015 (Pasparakis and Vandenabeele, 2015).
Koen Dewaele (CEO) started ADx about three and a half years ago, when Fujirebio (the former Innogenetics), cut back its research activities drastically. Four employees who already worked on Alzheimer’s biomarkers decided to continue the research and founded their own company. The company develops diagnostic tests to screen for Alzheimer’s.
The University Hospital Center in Liège is expanding. The new comprehensive cancer center will be ready in 2018. The center focuses on high quality integrated care, and a large part of the building will be dedicated to outpatients in consultation and day-care without overnight hospitalization. The center will offer multidisciplinary care, focused on the overall wellbeing of the patient.
What do Bone Therapeutics, Cardio3 Biosciences and Imcyse all have in common? They focus on stem cell therapy and are all linked to the Laboratory of Cell and Gene Therapy (LTCG) led by Yves Beguin, professor of hematology at the University of Liège and head of the hematology department at the University Hospital Center in Liège. Stem cell research is booming in Wallonia and much of it has originated from the lab of professor Beguin.
Peter Vandenabeele is senior full professor at the Inflammation Research Center (IRC), a VIB department at the Ghent University. He recently published in Nature an original research paper on the regulation of cell survival in vivo (Takahashi et al., 2014). RIPK1 (receptor interacting protein kinase 1) plays an important role both in the survival as well as in the death of epithelial cells. Full knockout mice for the Ripk1 gene are not viable. The team of Vandenabeele managed to make a viable conditional mouse model that lacks Ripk1 only in the intestinal epithelial cells. They also obtained in collaboration with people from GSK (Pennsylvania) a mouse model containing a mutant form of RIPK1 that lacks the kinase activity. Thanks to these genetic mouse models, mechanisms that regulate cell survival and cell death could be explored. Peter Vandenabeele and his team found that the platform function of RIPK lacking the kinase activity is associated with cell survival, while the kinase activity is associated with induction of cell death. Peter Vandenabeele also published a review paper in Nature about cell death pathways and inflammation in early 2015 (Pasparakis and Vandenabeele, 2015).
Koen Dewaele (CEO) started ADx about three and a half years ago, when Fujirebio (the former Innogenetics), cut back its research activities drastically. Four employees who already worked on Alzheimer’s biomarkers decided to continue the research and founded their own company. The company develops diagnostic tests to screen for Alzheimer’s.